EPI-002 and enzalutamide combination therapy as a potential therapeutic benefit for castration-resistant prostate cancer patients
Development of castration-resistant prostate cancer (CRPC) is thought to be dependent on androgen receptor (AR) transcriptional activity. Resistance to current therapies is linked to constitutively active AR splice variants that lack the ligand-binding domain (LBD). Metastatic tumours heterogeneousl...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2014
|
| Online Access: | http://hdl.handle.net/2429/50092 |